You are here: Knowledge Bank Press Releases

Press Releases

Press Releases is unique and effective promotional tool offered from aimed at bringing our client’s business message into limelight and more importantly make it reach their target audience. This feature can be utilized to launch new product, promoting existing Pharma product, publish business agreements, annual reports, financial results, corporate performances, important announcements or any important information that has to be conveyed to the target audience.

To add free press releases please click here.

Pall Purchases Exclusive License to Cutting-Edge Acoustic Wave Separation Technology from FloDesign Sonics for Biopharm Application

E-mail Print PDF

PORT WASHINGTON, N.Y. – June 15, 2015 – Pall Corporation, a global leader in filtration, separation and purification, announced the signing of an exclusive license for acoustic wave separation (AWS), a disruptive technology from FloDesign Sonics (FDS) for cell culture clarification for both fed-batch and perfusion applications. The AWS technology enables very-high-efficiency continuous removal of the cells in a closed system without centrifugation, thereby streamlining a challenging step in the biologics manufacturing process within a small operating footprint. The technology will complement Pall's industry-leading STAXTM depth filtration products to enable continuous clarification of cell culture, enabling integration of the bioreactor with downstream processing.

Venturing into chemicals in France

E-mail Print PDF

Invest in Grenoble-Isère and Rhône Valley - ACHEMA 2015 Hall 9.2, stand D41 Adisseo, Hexcel, Vencorex, Arkema… major international chemical industry stakeholders are investing more than a billion euros in Grenoble-Isère and the Rhône Valley (France).

ThyssenKrupp Uhde Chlorine Engineers and McPhy Energy seal a strategic commercial alliance in the area of hydrogen generation

E-mail Print PDF

McPhy Energy to become ThyssenKrupp Uhde Chlorine Engineers’ exclusive supplier for high-capacity, high-pressure hydrogen generation equipment for the carbon-free mobility and renewable energy sectors


E-mail Print PDF

AMPO, a leading foundry specialising in stainless steel and high alloy castings, with over 50 years’ experience, is an international company with a clear ability for innovation and developing processes, products and technologies.

At Pack/Pharma Expo, DIR Technologies to Debut "Lite" Version of Thermal Image-driven Induction Seal Inspection Solution for Bottles

E-mail Print PDF

Viable for Non-Pharma Sectors such as Food and Cosmetics,

New Simplified System Provides Induction Sealing Integrity Analysis

for 100% of Bottles without Packaging Line Slowdown

Haifa, Israel – At Pack/Pharma Expo Las Vegas September 28-30, DIR Technologies, a provider of quality and process control solutions for pharmaceutical primary packaging, will debut a simplified version of its groundbreaking Induction Integrity Verification System (I2VS) for bottles, which employs a pioneering application of thermal imaging for induction integrity assurance.  The new I²VS Lite will be introduced at DIR Technologies’ show booth, N-806.

Bristol-Myers Squibb to Present Data from 14 Abstracts on Orencia (abatacept) at the European League

E-mail Print PDF

Bristol-Myers Squibb Company (NYSE:BMY) announced today that 14 abstracts on Orencia have been accepted for presentation at the 2015 annual meeting of the European League Against Rheumatism (EULAR), to be held June 10-13 in Rome, Italy. Several of this year’s abstracts will focus on the safety and efficacy of Orencia in rheumatoid arthritis (RA) patients with anti-citrullinated protein antibodies (ACPA), which is a marker of worse prognosis and more progressive disease.

Adding Investigational Agent Elotuzumab to Standard Treatment for Multiple Myeloma Significantly Reduced the Risk of Disease Progression, According to New Phase III Data from ELOQUENT-2 Trial Published in New England Journal of Medicine

E-mail Print PDF

Bristol-Myers Squibb Company (NYSE:BMY) and AbbVie (NYSE:ABBV) today announced that results from an interim analysis of its Phase III, randomized, open-label ELOQUENT-2 trial were published in the June 2 online edition of the New England Journal of Medicine. The trial (n=646) evaluated elotuzumab, an investigational immunostimulatory antibody, in combination with lenalidomide and dexamethasone (ELd) versus lenalidomide and dexamethasone alone (Ld) for the treatment of relapsed or refractory multiple myeloma. The study met its co-primary endpoints demonstrating superior progression-free survival (PFS) and overall response rate (ORR).

Bristol-Myers Squibb to Take Part in Goldman Sachs 36th Annual Global Health Care Conference

E-mail Print PDF

Bristol-Myers Squibb Company (NYSE:BMY) will take part in Goldman Sachs 36th Annual Global Health Care Conference on Tuesday, June 9, 2015, in Rancho Palos Verdes, CA. Michael Giordano, senior vice president, Head of Development, Oncology, will answer questions about the company at 11:40 a.m. EDT (8:40 a.m. PDT).

U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo+Yervoy Regimen in Patients with Previously Untreated Advanced Melanoma

E-mail Print PDF

Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the supplemental Biologics License Application (sBLA) for Opdivo (nivolumab)+Yervoy (ipilimumab) regimen in patients with previously untreated advanced melanoma. The FDA also granted Priority Review for this application. The projected FDA action date is September 30, 2015. This is the first regulatory milestone for an Immuno-Oncology regimen in cancer.

Opdivo (nivolumab) Demonstrates Superior Survival Compared to Standard of Care (docetaxel) for Previously-Treated Squamous Non-Small Cell Lung Cancer in Phase III Trial

E-mail Print PDF

Bristol-Myers Squibb Company (NYSE:BMY) today announced results from CheckMate -017, a Phase III, open-label, randomized study evaluating Opdivo (n=135) versus docetaxel (n=137) in previously treated patients with advanced squamous non-small cell lung cancer. At one year, Opdivo demonstrated an overall survival rate of 42% versus 24% for docetaxel, with a median overall survival of 9.2 months versus 6 months, respectively. In the trial, Opdivo reduced the risk of death by 41%, based upon a hazard ratio of 0.59 (95% CI, 0.44-0.79; P = 0.00025). The safety profile of Opdivo in CheckMate -017 was consistent with prior studies and favorable versus docetaxel. Findings from CheckMate -017 were published today in The New England Journal of Medicine and presented during an oral abstract session at the 51st Annual Meeting of the American Society of Clinical Oncology (Abstract #8009).

Page 1 of 74

  • «
  •  Start 
  •  Prev 
  •  1 
  •  2 
  •  3 
  •  4 
  •  5 
  •  6 
  •  7 
  •  8 
  •  9 
  •  10 
  •  Next 
  •  End 
  • »